Weight-Loss Drugs in Older Adults: The Muscle Question Stays Open
Graded Preliminary — a review of existing studies without its own pooled numbers; the authors note that data on muscle and physical performance in older adults are limited and inconsistent.
- Design
- Narrative review
- Participants
- N/A
- Duration
- —
- Funding
- Open access funding by the Scientific and Technological Research Council of…
With GLP-1 weight-loss drugs, people often lose lean mass, mostly muscle, along with fat.
Weight-loss drugs in the GLP-1 class, such as semaglutide and tirzepatide, reliably help people lose weight. But along with fat, people often lose lean mass, which is mostly muscle. In older adults, muscle loss with age is already a major concern.
A review gathered what is known so far. In one analysis that pooled many trials, treated people lost on average 0.86 kilograms more lean mass than comparison groups. In a large tirzepatide trial, fat mass fell by about a third and lean mass by almost 11 percent. There are also some encouraging signs. In single studies, less fat built up inside the muscle. People with type 2 diabetes walked somewhat farther in a six-minute walking test.
The authors stress that data on muscle amount, muscle quality and physical performance in older adults are limited and inconsistent. Many trials also included fairly healthy older people. Those with heart or kidney disease were often left out. The authors conclude that treatment should be paired with tailored strength training, enough protein and advice from a dietitian.
Conflict of Interest Disclosure: The authors declare no competing interests.
Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.